Abstract:Abstract Introduction N6‐methyladenosine (m6A) is the most prevalent modification that occurs in messenger RNA (mRNA), affecting mRNA splicing, translation, and stability. This modification is reversible, and its related biological functions are mediated by “writers,” “erasers,” and “readers.” The field of viral epitranscriptomics and the role of m6A modification in virus–host interaction have attracted much attention recently. When Epstein–Barr virus (EBV) infects a human B lymphocyte, it goes through three phases: the pre‐latent phase, latent phase, and lytic phase. Little is known about the viral and cellular m6A epitranscriptomes in EBV infection, especially in the pre‐latent phase during de novo infection. Methods Methylated RNA immunoprecipitation sequencing (MeRIP‐seq) and MeRIP‐RT‐qPCR were used to determine the m6A‐modified transcripts during de novo EBV infection. RIP assay was used to confirm the binding of EBNA2 and m6A readers. Quantitative reverse‐transcription polymerase chain reaction (RT‐qPCR) and Western blot analysis were performed to test the effect of m6A on the host and viral gene expression. Results Here, we provided mechanistic insights by examining the viral and cellular m6A epitranscriptomes during de novo EBV infection, which is in the pre‐latent phase. EBV EBNA2 and BHRF1 were highly m6A‐modified upon EBV infection. Knockdown of METTL3 (a “writer”) decreased EBNA2 expression levels. The emergent m6A modifications induced by EBV infection preferentially distributed in 3ʹ untranslated regions of cellular transcripts, while the lost m6A modifications induced by EBV infection preferentially distributed in coding sequence regions of mRNAs. EBV infection could influence the host cellular m6A epitranscriptome. Conclusions These results reveal the critical role of m6A modification in the process of de novo EBV infection.

Identification of an N6-methyladenosine-mediated positive feedback loop that promotes Epstein–Barr virus infection

RNA M6a Methylation Regulates Virus–host Interaction and EBNA2 Expression During Epstein–Barr Virus Infection

M6a-Binding Proteins: the Emerging Crucial Performers in Epigenetics

N6-methyladenosine modification—a key player in viral infection

N(6)‐methyladenosine‐binding protein YTHDF1 suppresses EBV replication and promotes EBV RNA decay

N6-methyladenosine and viral infection

Epstein-Barr virus suppresses N6-Methyladenosine modification of TLR9 to promote immune evasion

Regulation of Virus Replication and T Cell Homeostasis by N6-Methyladenosine

The role of N6-methyladenosine modification in the life cycle and disease pathogenesis of hepatitis B and C viruses

Regulation of Virus Replication and T Cell Homeostasis by N 6 -Methyladenosine

Pathogenic Roles of M6a Modification in Viral Infection and Virus-Driven Carcinogenesis.

Analysis of N6-Methyladenosine Modification of HBV RNA by Methylated RNA Immunoprecipitation

Global profiling reveals common and distinct N6-methyladenosine (m6A) regulation of innate immune responses during bacterial and viral infections

Pathogenic Roles of m6A Modification in Viral Infection and Virus-driven Carcinogenesis

Regulation of Antiviral Immune Response by N6-Methyladenosine of mRNA

m6A modification controls the innate immune response to infection by targeting type I interferons

N6-Methyladenosine modification of hepatitis B and C viral RNAs attenuates host innate immunity via RIG-I signaling

Infection Phase-Dependent Dynamics of the Viral and Host N6-methyladenosine Epitranscriptome in the Lifecycle of an Oncogenic Virus in Vivo

N 6 -Methyladenosine and Its Implications in Viruses

m6A Regulates the Stability of Cellular Transcripts Required for Efficient KSHV Lytic Replication

N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction.